drugset / Trial / NCT03085771

Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes

NCT03085771

Phase 2 Unknown 30 enrolled Karolinska University Hospital
RandomizedCrossoverQuadruple-blindTreatment

Summary

The general aim of this study is to investigate the influence of systemic administration of Desferal (Deferoxamine \[DFO\]) on the response to hypoxic challenge in patients with diabetes mellitus (DM). The investigation will elucidate if DFO can restore: * the impaired angiogenetic response to hypoxia in patients with type 1 DM. * the disturbed respiratory and cardiovascular regulation in response to hypoxia in patients with DM type 1

Timeline

Start
2017-01-01
Primary completion
2023-12-12
Completion
2024-12-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Deferoxamine Other / unclassified 50 mg/kg Intravenous